## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -32.5% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 29 oversold (REVERSION excluded per A/B test). Stock is in no-man's land without clear edge. Caution: momentum weakening (-29.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.86)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bearish (Bullish: 0, Bearish: 2)

**1. Ultragenyx Tumbles After Setrusumab Fails Two Trials**
- Source: Bloomberg.com | 20251229T145100 | Bearish | Relevance: 100%
- Ultragenyx Pharmaceutical Inc. shares plunged after its experimental drug, Setrusumab, failed to meet primary endpoints in two Phase 3 clinical trials for a rare genetic bone disease. The company's stock dropped 41% following the announcement, adding to a year-to-date decline. This failure marks a significant setback for Ultragenyx's drug development efforts.

**2. Investigation Underway: Ultragenyx Pharmaceutical Inc. (RARE) - Contact Levi & Korsinsky Over Securities Law Violations**
- Source: ACCESS Newswire | 20251229T141500 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) following a significant 43.49% stock price drop on December 29, 2025. This decline occurred after the company announced that its Phase III Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta failed to meet their primary endpoint of reducing annualized clinical fracture rates. Investors who suffered losses are encouraged to contact Levi & Korsinsky for a potential recovery under federal securities laws.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.36M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-29.3% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (9.2%): bears positioning against stock.
3. Long-term trend broken: trading 31.6% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 21% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.2B |
| Beta | 0.16 |
| 52W Range | $18.41 - $46.50 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from -3.2% to -32.5% (-29.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 36.5pp (needs >4.0% for momentum thesis). AM_20 at -32.4% indicates price below own 20MA trend. Underperforming sector by 33.6pp, stock-specific weakness. Below SMA200 (0.68x), long-term trend not supportive. MACD histogram bearish (-1.43), momentum weakening. RSI oversold at 29, potential bounce setup. Elevated volume (5.6x 20MA), institutional activity likely. OFD pattern: +F0H (Breakout).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -32.52% (CS: 50) | Weak |
| RSI_14 | 28.7 | Oversold |
| MACD Histogram | -1.43 | Bearish |
| vs SMA20 | 0.676x | Below |
| vs SMA50 | 0.681x | Below |
| vs SMA200 | 0.684x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $22.78
- **Stop Loss:** $17.86 (21.6% risk)
- **Target:** $27.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 268
- **Position Value:** $6,105.04
- **Portfolio %:** 6.11%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*